1.jpg)
Causaly, a leader in AI-driven biomedical research, launched Pipeline Graph on June 24, 2025, an AI-powered application designed to streamline competitive intelligence for life sciences R&D teams. By integrating insights into the drug discovery process, Pipeline Graph enables scientists to make faster, data-driven decisions on drug targets, reducing the risk of costly development programs.
Causaly launches Pipeline Graph for competitive intelligence in drug discovery.
AI tool integrates insights with preclinical research on a single platform.
Connects 500 million facts and 70 million relationships in a knowledge graph.
Eliminates manual effort by unifying data from literature, trials, and news.
Enhances target identification and commercial viability analysis.
Available July 2025, built on Causaly’s advanced AI platform.
Pipeline Graph addresses the inefficiencies of traditional competitive intelligence in drug discovery, where scientists rely on fragmented tools or external teams. By embedding insights into Causaly’s AI platform, it unifies scientific evidence, pipeline data, and safety and efficacy insights from sources like clinical trials, scientific literature, news, and websites. This enables researchers to evaluate drug targets with a comprehensive view of biomedical and competitive landscapes.
“The industry has been forced to settle for competitive intelligence products that lack AI innovation and require too much manual effort,” said Yiannis Kiachopoulos, co-founder and CEO of Causaly. “Pipeline Graph gives scientists an AI-native application built specifically for life sciences that brings competitive intelligence into preclinical research. We aim to help teams access structured and unstructured data – no matter if it’s external or internal – for complete biomedical and competitive information that accelerate discoveries to market.” The platform reduces manual effort, ensuring timely and accurate insights.
Built on Causaly’s knowledge graph, Pipeline Graph connects 500 million facts and 70 million directional relationships across eight relationship types, adding over four million data points monthly. It extends the capabilities of Causaly Discover and Causaly Deep Research, offering a single hub for research and competitive intelligence. This integration eliminates data silos, enabling scientists to connect target identification with commercial viability efficiently.
Pipeline Graph empowers scientists to make confident pipeline decisions earlier, potentially saving billions in development costs. Available in July 2025, it promises to transform how biopharmaceutical companies approach drug discovery. Leading firms like Novo Nordisk already leverage Causaly’s platform for enhanced research productivity, and Pipeline Graph is poised to further accelerate market-ready therapies.
Causaly’s Pipeline Graph sets a new standard for AI-driven drug discovery. By unifying competitive intelligence with preclinical research, it equips scientists with the tools to navigate complex biomedical data, drive innovation, and deliver effective therapies faster, reshaping the future of life sciences R&D.
Causaly is a leader in AI for the life sciences industry. Leading biopharmaceutical companies use the Causaly AI platform to find, visualize, and interpret biomedical knowledge and automate critical research workflows.
TechIntelPro empowers B2B technology decision-makers with the latest industry trends, deep insights, leadership perspectives and actionable intelligence to drive both organizational and professional milestones—and thrive on the tech pulse.